Marcia A. Testa, M.P.H., M.Phil., Ph.D. 23 Woodcliff Road Department of Biostatistics

Transcription

Marcia A. Testa, M.P.H., M.Phil., Ph.D.
MARCIA A. TESTA, M.P.H., M.Phil., Ph.D.
Curriculum Vitae
May 1, 2013
Address:
Home
23 Woodcliff Road
Wellesley Hills, MA 02481
Academic Office
Department of Biostatistics
Harvard School of Public Health
655 Huntington Avenue
Boston, MA 02115
Phone: 617-432-8181
Email : [email protected]
http://www.hsph.harvard.edu/faculty/marcia-testa/
Date & Place of Birth:
November 17, 1952. Waterbury, Connecticut, U.S.A.
Education
1974
Psychology
B.A.
Connecticut College, New London, CT
1976
Public Health
(Biostatistics)
M.P.H.
Yale University School of Medicine
Dept. of Epidemiology and Public Health
1977
Epidemiology
& Public Health
(Biostatistics)
M.Phil.
Yale University Graduate School
1980
Epidemiology
& Public Health
(Biostatistics)
Ph.D.
Yale University Graduate School
Minors - Mathematical Statistics and Epidemiology
Academic Appointments
1999 - pres
Senior Lecturer on Biostatistics
1987 – 99
Faculty Lecturer on Biostatistics
1987 – 90
Associate Clinical Professor (Adjunct)
University of Connecticut School of Medicine
Departments of Research in Health Education and Community Medicine
1
1986 – 87
Associate Professor
Director, Biostatistics Research Center
University of Connecticut Health Center
1979 –1986
Assistant Professor
Director, Biostatistics Research Center
Other Academic Positions and Professional Positions
2010 – pres
Director, Preparedness and Emergency Response Learning Center,
Division of Policy Translation and Leadership Development, Harvard
School of Public Health
1986 – present
Chairman and Founder of Phase V Technologies, Inc.
1985-86
Assistant to the Vice President for Health Affairs
Information Systems Development
Office of the Vice President and Executive Director
1979
Visiting Fellow, Laboratory of Theoretical Biology
National Cancer Institute, National Institutes of Health
1977 –78
Associate in Research and Teaching Fellow
Department of Epidemiology and Public Health
1975 –77
Associate in Research
Connecticut Cancer Epidemiology Unit
Honors and Distinctions
1973
Phi Beta Kappa
1973
Elected Student Fellow (American Psychological Association)
1974
Summa cum laude, Honors in Psychology, Connecticut College
1976
John H. Watkins Thesis Prize in Biometry, Yale
1993
Roger L. Nichols Excellence in Teaching Award , Harvard School of Public
Health
1995
Donald E. Francke Award for Best Publication, Drug Information Association
2008
2008 American Public Health Association Statistics Section Award
2
2012
Excellence in Teaching in Continuing Education Award, Harvard School of
Public Health
Recent Professional Elected Positions of Distinction
2002-2004
Section Councilor, Statistics Section, American Public Health Association
2005 & 09
Secretary, Statistics Section, American Public Health Association
2004-2006
Chair Elect, Chair, Past Chair, Statistics Section, American Public Health
Association
2006-2008
Governing Council, American Public Health Association
2005-pres
Town of Wellesley Board of Health, Massachusetts
2006-pres
Massachusetts Association of Health Boards, Executive Committee
2009
Secretary-Elect, Statistics Section, American Public Health Association
Professional Memberships
American Association for the Advancement of Science
American Public Health Association
Statistics Section Council Member, 1997 – 2000
Statistical Section Secretary-Elect 2001 -02, 2008
Statistics Section Secretary 2002 – 03, 2009
Statistics Section Newsletter Editor 2002 – 05
Statistics Section Chair-Elect 2003 – 2004
Statistics Section Chair 2004- 2005
Governing Councilor, 2006 – 2008
Statistics Section Secretary-Elect 2008-2009
100th Anniversary APHA Statistics Section Committee Chair
Epidemiology Section Member
Health Informatics and Information Technology
American Statistical Association - > 35 Year Lifetime Member
American Telemedicine Association
Association for Health Services Research
American Diabetes Association
Research Review Board (1997 – 2003)
Drug Information Association
Health Information and Management Systems Society
IEEE Society (Computing Section)
International Biometrics Society
International Society for Pharmacoepidemiology
International Society for Quality of Life Research
International Society For Pharmacoeconomics and Outcomes Research
Massachusetts Association of Health Boards (MAHB)
National Association of County and City Health Officials (NACCHO)
National Association of Local Boards of Health (NALBOH)
3
Consulting, Industry and Technology Transfer Experience
Consultant to pharmaceutical and health insurance industries. Co-founder with the University of
Connecticut Research and Development Corporation, 1987 and Chairman, Phase V
Technologies, Inc., Wellesley Hills, MA, a consulting and contract organization focusing on
health and technology assessment and analysis services and information systems.
Selected Research Grants
2/1993 - 3/1997
Statistical Methods for Quality-of-Life Outcomes Research
Agency for Health Care Policy and Research
Principal Investigator
1/1995 - 12/1997
Quality of Life and Cost-Effectiveness Analysis in the Treatment of
NIDDM
American Diabetes Association, Principal Investigator
9/1989 - 12/2003
National Institutes of Health
Senior Statistician
Statistical and Data Analysis Center (SDAC), Aids Clinical Trials Group
1999 - 2004
Making Advances in Jaundice (MAJIC) Quality of Care in Newborns
Agency for Health Care Policy and Research
Senior Statistician
2000 – 2007
The Impact of Wasting and Lipodystrophy on Quality of Life in Persons
with HIV
Unrestricted Educational Grant from Serono Labs
2000 – 2010
Statistical Methods for Measurement and Analysis of Health Outcomes
Data
Unrestricted Educational Grant from Phase V Technologies
2003 – 2010
Harvard School of Public Health Center for Public Health Preparedness a,
Centers for Disease Control and Prevention (CDC)
Co-Investigator and Director, Evaluation Core and Senior Evaluator
2008 – 2012
Linking Assessment and Measurement to Performance in PHEP Systems
(LAMPS), Harvard Center for Public Health Preparedness
Centers for Disease Control and Prevention (CDC)
Co-Investigator and Director, Mentorship Program for Research Fellows),
Head “New Research Investigators and Pilot Projects”
4
2011 – 2012
Hazard Vulnerability Analysis to Enhance Public Health Preparedness in
Connecticut, State of Connecticut/Department of Public Health, Role
Currently Active Grants
2010 – pres
HSPH Preparedness and Emergency Response Learning Center (PERLC)
Centers for Disease Control and Prevention
Principal Investigator and Director
Period of Award: 09-29-2010 – 09-30-2015
Original Award Amount: $4,688,285
Pending Grant Application (As Principal Investigator)
Pending
Comparing local public health department approaches to improving
community-based preventive health care services
Patient-Centered Outcomes Research Institute (PCORI)
Role: Principal Investigator
Submitted: 12-17-2012; Period: 07-01-2013 – 06-31-2016
Direct Costs: $1 ,334,367 Indirect: $ 523,747 Total: $ 1,858,113
Pending:
Building Capacity of the Public Health System to Improve Population
Health through National, Nonprofit Organizations
Centers for Disease Control and Prevention (CDC) – subcontract through
National Haitian Health Alliance
Submitted: 03-04-2013; Period: 07-01-2013 – 06-31-2016
Direct Costs: $1,865,475 Indirect: $839,464 Total: $2,704,939
Pending:
Benchmarking the Comparative Effectiveness of Diabetes Treatments
Using Patient-Reported Outcomes and Socio-demographic Factors
Patient Centered Outcomes Research Institute (PCORI)
Submitted: 04-12-2013 Period: 09-01-2013 to 08-31-2016
Direct Costs: $1,692,080 Indirect: $417,899 Total: $2,109,979
Pending:
Disaster Mental Health: Evaluation of Hurricane Sandy Crisis Counseling
Program
DHHS/Assistant Secretary for Preparedness and Response
Submission Date: 05-20-2013; Period: 08-15-2013 to 08-14-2016
Direct Costs: $500,000
Indirect: $307,500 Total: $807,500
Pending:
Effectiveness of Risk Communication and Social Media in Response to
Hurricane Sandy
DHHS/Assistant Secretary for Preparedness and Response
5
Submission Date: 05-20-2013; Period: 08-15-2013 to 08-14-2016
Direct Costs: $500,0 Indirect: $307,500 Total: $807,500
Teaching – Graduate Courses
Harvard School of Public Health and Harvard Medical School
Primary Instructor
 Bio 200s, Principles of Biostatistics (1994, 95, 96, 97, 98, 99, 2000, 2001)
(2.5 cr.)
 Bio 201ab, Introduction to Statistical Methods (1991, 92, 93, 94) (5 cr.)
 Bio 202/Session 1, Principles of Biostatistics (2002, 2003, 2004, 2005,
2006, 2007, 2008, 2009, 2010, 2011, 2012) (2.5 cr.)
 Bio 203ab, Statistical Methods for Health Policy and Management (1987,
88) (5 cr.)
 Bio 210cd, Rates and Proportions (1996) (5 cr.)
 Bio 218d, Database Systems and Architecture (1988, 89, 90, 91) (2.5 cr)
 Bio 219ab, Statistical Methods for Health Policy and Management (1995,
96, 97, 98, 99) (5 cr.)
 Bio 262cd, Statistical Problems in Drug Development (1990, 92, 94, 96,
98, 99) (2.5cr)
 EPB 253c, Information Management and Data Resources for
Epidemiology (2000, 2001, 2002) (2.5 cr.)
 HCP 502, Medical Decision Making and Clinical Epidemiology (1988,
89, 90, 91, 92)
 HPM 514, Developing Questionnaires for Measuring the Outcomes of
Health Care ( 2005) (2.5 credits)
 *HPM 530, Measuring and Analyzing the Outcomes of Health Care (
2006, 2007, 2008, 2009, 2010, 2011, 2012) (2.5 credits)
 ID 253c, Information Management in Epidemiology (2003, 2004) (2.5
credits)
 ID 265, Practice of Quantitative Methods (1999, 2000, 2001, 2002, 2003,
2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013) (2.5 cr.)
 ID 270/370, MPH Quantitative Methods Practicum (2000, 2001, 2002,
2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013) (5 r.)
 ID 538 Foundations of Public Health (2008) (10 cr.) – responsible for
Local Public Health Case Study and Biostatistics Requirement (59
students)
Lecturer ( Selected titles for 1 or more sessions)
 Bio 269cd, Psychiatric Statistics (1992-94)
 ID 265bc, Practice of Quantitative Methods (1995, 96, 97, 98)
 Bio 287, Public Health Surveillance (2008, 2009, 2010, 2012, 2013)
6


Human Phenotyping, Scholars in Clinical Science Program, Harvard
Medical School (2000, 01)
TIMI Grand Rounds, Harvard Medical School, (2008)
Continuing Medical/Professional Education Courses – HSPH
Course Director (CME/CPE Approved)
 Measurement, Design and Analysis Methods for Outcomes Research
(1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007,
2008, 2009, 2010, 2011, 2012), HSPH Center for Continuing Professional
Education, 28 CME credit hours
 Outcomes Research (June 1997, 98, 99, 2000), Mediterranean School of
Medical Statistics and Clinical Epidemiology, HSPH Center for
Continuing Professional Education, 21 CME credit hours.
 Outcomes Research (June 2003), Summer School on Modern Methods in
Biostatistics and Epidemiology (Treviso, Italy) HSPH and Karolinska
Institute, Sweden.
 Quality of Life and Pharmacoeconomics in the Treatment of Diabetes.
(June 1996), HSPH Center for Continuing Professional Education, 2 CME
credit hours, Course Director.
 Costs and Benefits of Diabetes Treatment: A Health-economics
Perspective (June 1997, HSPH Center for Continuing Professional
Education, 2 CME credit hours, Course Director.
 The Harvard Conference on American Conference on Health Care: Using
Outcomes Research to Evaluate and Manage Quality and CostEffectivneess of Health Care – a One Day Workshop (November 2000,
2001, 2002), Course Director
 Lecturer on Health Outcomes Research Measurement, Patient Satisfaction
and Trust – 2 - 3 HSPH Continuing Education Programs organized by
David Shore each year (2000, 2001, 2002, 2003)
 Statistical Issues in Drug Development, Kitasato University, 30 hours,
(October, 2007)
Preparedness and Emergency Response Learning Center (PERLC) Distance Learning
As Director, Dr. Testa has organized the development of a series of distance learning programs
and courses in preparedness and emergency response which can be found on the CDC TRAIN
(www.train.org) , HRSA Public Health Training Center Network
http://bhpr.hrsa.gov/grants/publichealth/trainingcenters/search.html
and the HSPH PERLC Website www.hsph.harvard.edu/hperlc including courses on Model
Leadership (9 lectures); Communicate and Manage Information (3 lectures); Plan for
Emergencies (5 lectures) and Evaluate and Improve Practice (4 Lectures).
Doctoral Student Dissertation Advising
Carolyn Schwartz, Health and Social Behavior,1989-90
Susan Andrade, Epidemiology (Pharmacoepidemiology) ,1991-95
7
Susan Oliveira, Epidemiology, (Pharmacoepidemiology) 1992- 95
Sharon Milberger, Epidemiology (Psychiatric Epidemiology) 1993 - 95
Hideki Inatori Hashimoto, Health and Social Behavior, 1996 - 99
Constance Bacon, Health and Social Behavior, 1998 - 2000
Max Su, Biostatistics, 1998 – 2002
Kristen Snow, Epidemiology, 1998 - present
Chen-Chang Yang, Epidemiology, 2000 – 2002
Kristen Snow, Epidemiology, 1998 - present
Linda Marc, Health and Social Behavior, 2001 - 2005
Yinong Young-Xu, Epidemiology, 2001 – 2005
Allison Smitten, Epidemiology, 2002-2006
MPH in Quantitative Methods Practicum Teaching and Advising
All MPH students are required to undertake a Practicum and “Culminating Experience”
as part of the requirements for the MPH program. For MPH students concentrating in
Quantitative Methods the Culminating Experience is a project that is undertaken during the
Spring 1 session in conjunction with the ID 265 “Practice of Quantitative Methods” course or
during the year by those enrolled in the Summer Only QM program by taking ID 370 Fall,
Winter, Spring and Summer. I have acted as the Practicum Advisor for 50% of full-time MPH
QM students (approximately 40-45 students per year) during the periods 1996 - 2013 I am also
the Director of the Summer Only QM MPH program as well as the primary instructor for the
Summer Only QM MPH ID270 course which requires that the student undertake larger research
projects off site during the non-Summer months. I have served as the HSPH project advisor for
more that 30 of these students to date. Project presentations are given during Summer 1 and
Summer 2 noon seminars and are attended by all QM and Clinical Effectiveness MPH
candidates.
University of Connecticut Schools of Medicine and Dental Medicine
1979-1987
Faculty, Biostatistics Subject Committee
Epidemiology Subject Committee
1985-1987
Chairman, Biostatistics Subject Committee
University of Connecticut Graduate School
1980-1987
Introduction to Biostatistics, Computer Systems and
Intermediate Statistical Methods (M.P.H. Program)
1982-1987
Biostatistical Methods in Medical Research
Applied Biostatistical Methods
Graduate Theses
Ph.D. Yale University, 1980: “Modeling population responses of compartmental systems with
application to insulin-glucose kinetics in young, old and diabetic individuals”.
Description: Using data obtained from insulin clamp studies this thesis developed a random
effects statistical model and computer program for the estimation of population compartmental
pharmacokinetic parameters describing the relationship between glucose intolerance, type 2
diabetes and insulin resistance.
8
M.P.H. Yale University, 1976: Mathematical modeling of cancer incidence rates: Linear
models of colon cancer in Connecticut.
Practice Experience in Public Health and Consulting
Since 2004 Dr. Testa has been an elected Board of Health (BOH) member in Wellesley,
Massachusetts, serving 27,000 residents 1. The Board directs the Health Department
environmental, community, nursing and mental health practice and programs setting a leadership
BOH standard for the 351 BOHs in the Commonwealth and for local health department
nationally. The Wellesley BOH was one of the first in the nation to receive the National
Association of County and City Health Officials (NACCHO) Public Health Ready status. She
is a member of the Massachusetts Emergency Preparedness Region 4b (27 towns) Committee 2
and a Medical Reserve Corp Volunteer 3. She has served on the Executive Board of the
Massachusetts Association of Health Boards (MAHB), an affiliate of the National Association of
Local Boards of Health, (NALBOH) 4 since 2005 which provides education, technical assistance,
representation, and resource development. She has worked with the Association of Schools of
Public Health (ASPH) 5 developing Core competencies and certification examinations (CPH) as
part of the National Board of Public Health Examiners 6. Dr. Testa has taught over 100 academic
for-credit courses and 30 executive education courses in public health (biostatistics,
epidemiology, health policy and management, health services and public health practice). She is
the co-director of HSPH’s MPH in Quantitative Methods program. Dr. Testa has been a CoInvestigator of the Harvard Center for Public Health Preparedness (HCPHP) during which time
she established the Center’s first Evaluation Core. She is currently the Director of the CDCsponsored HSPH Preparedness and Emergency Response Learning Center (PERLC) 7, Center for
Public Health Preparedness 8 within the Division of Policy Translation and Leadership
Development 9. She has been a member of the American Public Health Association 10 since 1982
serving as Statistics Section Councilor, Secretary, Chair, and APHA Governing Councilor. In
2008 she received the APHA Statistics Award for excellence in teaching and practice. In her
leadership role in public health preparedness, Dr. Testa chaired the national CDC Preparedness
Education Planning and Evaluation Network Activity and participated in the Evaluation 101 and
University-based Student Preparedness Education CDC Exemplar Workgroups, and the CDC
CPHP Collaboration Group: State and Local Partnerships. Dr Testa has also served as a CoInvestigator, HSPH Preparedness and Emergency Response Research Center (PERRC) and as
Director of New Investigator Training and Pilot Projects 2008 – 2013. Dr. Testa also has served
as a consultant to the pharmaceutical and device industries through Phase V Technologies,. a
University of Connecticut venture established in 1986 focusing on patient-centered outcomes and
1 http://www.ci.wellesley.ma.us/Pages/WellesleyMA_Health/index.,
2 http://www.region4b.org/Region4bCommunities.aspx
3 https://www.medicalreservecorps.gov/HomePage
4 http://www.mahb.org/
5 http://www.asph.org/
6 http://www.nbphe.org/
7 http://www.cdc.gov/phpr/perlc.htm
8 http://www.hsph.harvard.edu/policy-translation-leadership/emergency-preparedness-and-response/
9 http://www.hsph.harvard.edu/policy-translation-leadership/
10 http://www.apha.org/
9
comparative effectiveness research. She is currently a member of the Patient-Centered
Outcomes Research Institute’s (PCORI) 11 Methods Study Section.
Peer-reviewed Publications
1. Desiderato O, and Testa MA. Shock stress, gastric secretions and habituations in the
chronic fistula rat. Physiology and Behavior 1976;16:67-73. (PMID: 944928)
2. Testa MA and Meigs JW. Mathematical modeling of cancer incidence rates: Linear
models of colon cancer in Connecticut. J Chronic Dis 1980;33:733-743. (PMID: 7430325)
3. Krishnamohan VK, Wheeler MB, Testa MA and Philipps AF. Correlation of postnatal
regression of the anterior vascular capsule of the lens to gestational age. J Pediatric
Ophthalmology and Strabismus 1982;19(1):28-32. (PMID: 7069563)
4. Holmes G, Rowe J, Hafford J, Schmidt R, Testa M and Zimmerman A. Prognostic value
of the electroencephalogram in neonatal asphyxia. Electroencephalography and Clinical
Neurophysiology 1982;53:60-72. (PMID: 6173201)
5. Cieplinski W, Reardon P and Testa, MA. Non-random human chromosome distribution
in human-mouse myeloma somatic hybrids. Cytogenetics and Cell Genetics
1983;35:93-99. (PMID: 6851676)
6. Gettinger G, Patters MR, Testa MA, Loe H, Anerud A, Boysen H, and Robertson PB. The
use of six selected teeth in population measures of periodontal status. J Periodontology
1983;54:3. (PMID: 6573472)
7. Dore-Duffy P, Catalanotto F, Donaldson JO, Ostrom KM and Testa MA. Zinc in multiple
sclerosis. Ann Neur 1983;14:450-454. (PMID: 6195958)
8. Levin RE, Testa MA, Weinstein A, Peterson M and Rothfield NF. A comparison of the
sensitivity of the 1971 and 1982 American Rheumatism Association criteria for the
classification of systemic lupus erythematosus. Arthritis and Rheumatism
1984;27:530-538. (PMID: 6721885)
9. KROC Collaborative Study Group (MA Testa, co-author). Blood glucose control and the
evolution of diabetic retinopathy and albuminuria: A preliminary multicenter trial. N Engl
J Med 1984;311:365-372. (PMID: 6377076)
10. Tanzer JM, Borjesson AC, Laskowski L, Kurasz AB and Testa M. GlucoseSucrose-Potassium Tellurite-Bacitracin agar: An alternative to Mitis Salivarius-Bacitracin
Agar for enumeration of Streptococcus mutans. J Clin Microbiology 1984; 20:653-659.
(PMID: 6490852)
11. Catalanotto FA, Dore-Duffy P, Donaldson JO, Testa M, Peterson M and Ostrom KM.
Quality-specific taste changes in multiple sclerosis. Ann Neur 1984; 16:611-615. (PMID:
6508242)
12. Passas CM, Wong RL, Peterson M, Testa MA and Rothfield NF. A comparison of the
specificity of the 1971 and 1982 American Rheumatism Association criteria for the
classification of systemic lupus erythematosus. Arthritis and Rheumatism
1985;28:620-623. (PMID: 4004972)
13. Bartlett RC, Mazens MF and Testa MA. Differentiation of Psuedomonas aeruginosa and
Enterobacteriaceae in direct smear based on measurements by scanning electron
11 http://www.pcori.org/
10
microscopy. Diagn Microbiol Infect Dis 1985;3:143-147. (PMID: 3919992)
14. Kohner EM, Lawson PM, Ghosh G and Testa M. Assessment of angiograms. Diabetes
1985;34(Suppl. 3):56-60.( PMID: 4018421)
15. Testa MA, Puklin JE, Simonson DC and Sherwin RS. Clinical predictors of retinopathy
and its progression in patients with Type I diabetes during continuous subcutaneous insulin
infusion or conventional insulin treatment. Diabetes 1985; 34(Suppl. 3):61-68. (PMID:
3894129)
16. Lundy J, Thor A, Maenza R, Schlom J, Forouhar F, Testa M and Kufe D. Monoclonal
antibody DF3 correlates with tumor differentiation and hormone receptor status in breast
cancer patients. Breast Cancer Research and Treatment 1985;5:269-279. (PMID: 2992647)
17. Testa MA and Simonson DC. The design and structure of clinical research information
systems: Implications for data retrieval and analysis. J Med Systems 1985;9:109-119.
(PMID: 3840516)
18. Peterson MGE and Testa MA. Rank order scaling in taste evaluation. Computers and
Biomed Research 1986;19:56-62. (PMID: 3753915)
19. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL and
Williams GH. The effects of antihypertensive therapy on the quality of life. N Engl J Med
1986;314:1657-1664. (PMID: 3520318)
20. Testa, MA: Quality of life during antihypertensive therapy: Techniques for clinical
assessment and evaluation, Br J Clin Pharmacology 1987;23:9S-13S. (PMID: 3580259)
21. Testa, MA. Interpreting quality of life clinical trial data for use in the clinical practice of
antihypertensive therapy, J Hypertension 1987;5 (Suppl. 1):S9-S13. (PMID: 3553497)
22. Williams GH, Croog SH, Levine S, Testa MA and Sudilovsky A. Impact of
antihypertensive therapy on quality of life: Effect of hydrochlorothiazide. J Hypertension
1987;5(Suppl. 1):S29-S35. (PMID: 3553493)
23. Croog SH, Levine S, Testa MA and Sudilovsky A. Work performance and
antihypertensive medications: A comparison of captopril, methyldopa and propranolol. J
Hypertension 1987;5(Suppl. 1):S47-S54. (PMID: 3553496)
24. Levine S, Croog SH, Sudilovsky A and Testa MA. Antihypertension and life satisfaction.
Quality of Life and Cardiovascular Care 1987:3:26-28.
25. Levine S, Croog SH, Sudilovsky A and Testa MA. Effects of antihypertensive
medications on vitality and well-being. J Family Practice 1987 25:357-363. (PMID:
3309131)
26. Pinkerton RE, Garibaldi RA, Conrad C, Bush F, Brown DH, Testa MA, Mancini L, Lerer
TJ, Ryan R, Aukerman G and Tilton R. Urinary tract symptoms in rural New England
family practice: A microbiologic evaluation. J Amer Board of Family Practice
1988;1:39-45. (PMID: 3414387)
27. Williams GH and Testa MA. Quality of life and its assessment in treating hypertension.
Current Opinion in Cardiology 1988:3 (Supplement 1);577- 581.
28. Testa MA and Simonson DC. Measuring quality of life in hypertensive patients with
diabetes. Post Graduate Medical Journal 1988: 64(Supplement);50-58. (PMID: 3249717)
29. KROC Collaborative Study Group (M. Testa, Co-author). Diabetic retinopathy after two
years of intensified insulin treatment. Follow-up of KROC Collaborative Study, JAMA
1988; 260:37-41.(PMID: 2898025)
30. Spackman TJ, Peccei R, and Testa MA. Commercial research and development in times of
11
financial restraint, Investigative Radiology 1988; 23:791-794. (PMID: 3192401)
31. Testa MA, Sudilovsky A, Rippey R and Williams GH: A short form for the clinical
assessment of quality of life in hypertensive patients. Amer J Prev Med 1989;5:82-89.
(PMID: 2659046)
32. Sudilovsky A, Croog SH, Crook T, Turnbull B, Testa MA, Levine S and Klerman GL.
Differential effects of antihypertensive medications on cognitive functioning.
Psychopharmacology Bulletin 1989; 25: 133-138. (PMID: 2772112)
33. Schoenberger JA, Testa M, Ross AD, Brennan WK, Bannon JA. Efficacy, safety and
quality of life assessment of captopril antihypertensive therapy in clinical practice. Archives
of Internal Medicine, Arch Intern Med 1990; 150:301-306. (PMID: 2405803)
34. Testa MA, Hollenberg NK, Anderson RA, Williams GH. Assessment of quality of life by
patient and spouse during antihypertensive therapy with atenolol and nifedipine GITS. Am
J Hypertens 1991; 4:363-373. (PMID: 2059396)
35. Hollenberg NK, Testa M, and Williams, G. Quality of Life as a therapeutic endpoint: An
analysis of therapeutic trials in Hypertension, Drug Saf 1991;6:83-93. (PMID: 2043286)
36. Gelber RD, Lenderking WR, Cotton DJ, Cole B, Fischl MA, Goldhirsch A and Testa MA.
Quality-of-life evaluation in a clinical trial of zidovudine therapy for patients with mildly
symptomatic HIV infection. Ann Intern Med 1992;116:961-966. (PMID: 1586104)
37. Testa MA and Lenderking WR. Interpreting pharmacoeconomic and quality-of-life clinical
trial data for use in therapeutics. PharmacoEconomics 1992;2:107-117. (PMID:10146951)
38. Testa MA. Parallel perspectives on quality of life during antihypertensive therapy: Impact
of responder, survey environment and questionnaire structure. J Cardiovas Pharmacol
1993;21:S18-S25. (PMID: 7692146)
39. Testa MA, Anderson RB, Nackley JF and Hollenberg NK: Quality of life and
antihypertensive therapy in men: A comparison of captopril with enalapril, N Eng J Med
1993;328:907-13. (PMID: 8446137)
40. Testa MA, Nackley JF. Methods for quality-of-life studies. Annu Rev Public Health
1994;15:535-59. (PMID: 8054098)
41. Anderson RB and Testa, MA. Symptom distress checklists as a component of quality-oflife measurement: Comparing prompted reports by patient and physician with concurrent
adverse event reports via the Physician. Drug Inf J 1994;28:89-114.
42. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA and Testa
MA. Evaluation of quality of life associated with zidovudine therapy in asymptomatic
human immunodeficiency virus infection. N Engl J Med 1994;330:738-43. (PMID:
7906386)
43. Parker JD, Testa MA, Jimenez AH, Tofler GH, Muller JE, Parker JO and Stone PH.
Morning increase in ambulatory ischemia in patients with stable coronary artery disease:
Importance of physical activity and increased cardiac demand. Circulation 1994;89:604614. (PMID: 8313548)
44. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Sapieria GM, Platt R.
Discontinuation of antihyperlipidemic drugs -- Do rates reported in clinical trials reflect
rates in primary care settings? N Engl J Med 1995:332:1125-31. (PMID: 7700285)
45. Anderson RB, Nackley JF, Testa MA. Symptom distress check lists as a component of
quality of life measurement: Comparing symptom reports with responses to multiple choice
questionnaires. Drug Inf J 1995; (1689S-1707S).
12
46. Testa MA and Lenderking WR. Quality of life considerations in clinical trials of persons
with HIV infection" in AIDS Clinical Trials (Eds., Finkelstein D and Schoenfeld D),
Wiley-Liss,New York, 1995, pp 213-241.
47. El-Hajj Fuleihan G, Testa MA, Angell JE, Porrino N, LeBoff MS. Reproducibility of
dual-energy X-ray absorptiometry: A model for bone loss estimates. J Bone Miner Res
1995:10;1004-1014. (PMID: 10160084)
48. Lenderking WR, Nackley JF, Anderson RB, Testa MA. A review of quality-of-life aspects
of urinary urge incontinence. PharmacoEconomics 1996;9:11-23. (PMID: 10160084)
49. Testa MA and Simonson DC. Assessing quality-of-life outcomes. N Engl J Med
1996;334:835-840. (PMID: 9809729)
50. Testa MA. The Medical Outcomes Study. (Letter), JAMA 1996; 275:1083. (PMID:
8601917)
51. Milberger S, Faraone SV, Biederman J, Testa M, Tsuang MT. New phenotype definition of
attention deficit hyperactivity disorder in relatives for genetic analyses. American Journal
of Medical Genetics 1996; 67(4):369-77.(PMID: 8837705)
52. Gill PS. Mitsuyasu RT, Montgomery T, Huang J. Cabriales S. Testa M, Espina BM,
Levine AM, Miles SA. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV
chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's
sarcoma . Cancer Journal from Scientific American. 1997; 3(5):278-83. (PMID: 9327151)
53. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B,
Northfelt DW, Huan J, Tulpule A, Levine A for the NIAID AIDS Clinical Trials Group.
Randomized trial of standard-dose vs. Low-dose mBACOD chemotherapy for HIVassociated non-Hodgkin’s lymphoma. N Engl J Med 1997;336:1642-8. (PMID: 9171066)
54. Lenderking WR, Testa MA, Katsenstein D, Hammer S. Measuring quality of life in HIV
disease: the modular approach. Qual Life Res 1997;6:515-530. (PMID: 9330552)
55. Carroll J, Testa MA, El-Hajj Fuleihan G. Modeling fracture risk using bone density, age
and years since menopause. Amer J Prev Med, 1997;13:447-452. (PMID: 9415791)
56. Krown SE, Testa M, Huang J. AIDS-related Kaposi’s Sarcoma: Prospective validation of
the AIDS Clinical Trials Group staging system. Journal of Clinical Oncology 1997;
15:3085-3092. (PMID: 9294471)
57. Testa MA and Turner RR. Assessment of quality of life in hypertension and its bearing on
compliance. International Journal of Clinical Practice 1997; Suppl. 92:19-22.
58. Testa MA, Quality of life, adherence and antihypertensive therapy (In Japanese) .
Presented at the 95th Japanese Society of Internal Medicine, Fukuoka, Japan. Circulation
Insights, Life Sciences Publishing. Summer, 1998 (No. 2): 8-13.
59. Testa MA, Simonson DC, Turner RR. Valuing quality of life and improvements in
glycemic control in people with type 2 diabetes, Diabetes Care. 1998; 21 (Suppl 3):C44C52. (PMID: 9850489)
60. Straus DJ, Huang J, Testa MA, Levine AM and Kaplan LD. Prognostic factors in the
treatment of human immunodeficiency virus --Associated non-hodgkin's lymphoma.
Analysis of AIDS Clinical Trials Group Protocol 142 -- low dose vs. standard dose mBACOD plus granulocyte-macrophage colony stimulating factor, Journal of Clinical
Oncology. 1998; 16;3601-3606. (PMID: 9817281)
61. Testa MA, Simonson DC. Health economic benefits and quality of life during improved
glycemic control in patients with type 2 diabetes mellitus: A randomized controlled,
13
double-blind trial. JAMA; 1998;280:1490-1496. (PMID: 9809729)
62. Testa MA, Turner RR, Krafcik MB, Simonson DC, Calvo C, Luque-Otero M. and the
Nifedipine GITS Study Group. Quality of life and calcium channel blockade with
nifedipine GITS versus amlodipine in hypertensive patients in Spain. Journal of
Hypertension 1998; 16:1839-1847 (PMID: 9869019)
63. Testa MA and Lenderking WR. The impact of AIDS-associated wasting on quality of life:
Qualitative issues of measurement and evaluation. Journal of Nutrition, 1999;129:282S289S. (PMID: 9915916)
64. Lenderking WR, Tennen H, Nackley JF, Hale MS, Turner RR , Testa MA. Effects of
venlafaxine on social activity level in depressed outpatients. J Clin Psychiatry 1999;
60:157-163. (PMID: 10192590)
65. Rabkin CS, Testa MA, Huang J, Von Roenn JH. Kaposi's Sarcoma and non-hodgkin's
lymphoma incidence trends in AIDS Clinical Trials Group Study Partcipants, Journal of
AIDS, J Acquir Immune Defic Syndr 1999 Aug 1;21 Suppl 1:S31-3. (PMID: 10430216)
66. Blonde L, Dey J, Testa MA, Guthrie D. Defining and measuring quality of diabetes care.
Diabetes 1999:26;841-855. (PMID: 10523463)
67. Turner RR and Testa MA. Measuring the impact of onychomycosis on patient quality of
life. Quality of Life Research 2000; 9:39-53. (PMID: 10981205)
68. Testa MA. Quality -of-Life Assessment in diabetes research: Interpreting the magnitude
and meaning of treatment effects. Diabetes Spectrum 2000:13; 29-35.
69. Testa MA. Interpretation of quality of life outcomes: Issues that affect magnitude and
meaning. Medical Care 2000;38 [suppl II]:II-166-II-174. (PMID: 10982103)
70. Testa MA. Methods and applications of quality-of-life measurement during
antihypertensive therapy. Curr Hypertens Rep. 2000 (6):530-7. (PMID: 11062598)
71. Langley PC, Testa MA. Can you measure the quality of this life? Interview by Lauren M.
Walker. Bus Health 2000 Oct;18(9):42-4, 47-8. (PMID: 11141794)
72. Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality
of life outcomes for patients with localized prostate cancer. J Urol 2001 Nov;166(5):180410. (PMID: 11586228)
73. Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I. The association of treatmentrelated symptoms with quality-of-life outcomes for localized prostate carcinoma patients.
Cancer 2002; 94:862-71. PMID: 11857323
74. Krown SE, Li P, Von Roenn JH, Paredes J, Huang J and Testa MA. Efficacy of low –dose
interferon with antiretroviral therapy in Kaposi’s sarcoma: A randomized Phase II AIDS
Clinical Trials Group Study. Journal of Interferon and Cytokine Research 2002; 22:295303. (PMID: 12034036)
75. Evans SR. Krown SE. Testa MA. Cooley TP. Von Roenn JH. Phase II evaluation of lowdose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's
sarcoma: an AIDS Clinical Trials Group clinical study. Journal of Clinical Oncology 2002;
20:3236-41. (PMID: 12149296)
76. Miles SA, Testa M, Huang J, Wade M, Carden J, Scadden DT. Lack of antitumor activity
and intolerance of interleukin-4 in patients with advanced HIV disease and Kaposi's
sarcoma. J Interferon Cytokine Res. 2002 Nov;22(11):1143-8. (PMID:12513914)
77. Yang CC, Jick SS, Testa MA. Who receives lipid-lowering drugs: the effects of
comorbidities and patient characteristics on treatment initiation. British Journal of Clinical
14
Pharmacology 2003; 55, 288-298. (PMID: 12630980, PMCID: PMC1884220)
78. Yang CC, Jick SS, Testa MA. Discontinuation and switching of therapy after initiation of
lipid-lowering drugs: the effects of comorbidities and patient characteristics. Br J Clin
Pharmacol. 2003; 56: 84-91. (PMID:12848779, PMCID: PMC1884321)
79. Testa, MA. Improving diabetes therapy: Improving satisfaction. Diabetes Voice 2003;
48: 23 – 25.
80. Chou SC, Heather Palmer R, Ezhuthachan S, Newman C, Pradell-Boyd, B, Maisels J,
Testa MA. Management of Hyperbilirubinemia in Newborns: Measuring Performance by
Using a Benchmarking Model. Pediatrics 2003; 112: 1264-1273. (PMID:14654595)
81. Reynolds NR, Testa MA, Marc L, Chesney MA Neidig JL, Smith SR, Vella S, Robbins
GK for the Protocol Teams of ACTG 384, ACTG 731 and A5031s. Factors influencing
medication adherence beliefs and self-efficacy in persons naïve to antiretroviral therapy: a
multi-center, cross-sectional study. AIDS and Behavior, 2004; 8:141-150.
(PMID:15187476)
82. Savoia E, Morano J, Cote D, Rampal S, Villa D, Testa MA. Public health preparedness
evaluation and measurement. Italian Journal of Public Health. 2004;1(1-2):56.
83. Palmer RH, Ezhuthachan S, Newman C, Maisels MJ, Testa MA. Hyperbilirubinemia
benchmarking. Pediatrics. 2004 Sep;114(3):902-4 (PMID: 15342882)
84. Palmer RH, Ezhuthachan S, Newman C, Maisels MJ, Testa MA. Management of
hyperbilirubinemia in newborns: measuring performance using a benchmarking model..
Pediatrics. 2004 Sep;114(3):902. (PMID: 15342881)
85. Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A,
Jiang H, Gulick RM. Four measures of antiretroviral medication adherence and virologic
response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr. 2005 Nov
1;40(3):301-6. (PMID: 16249704)
86. Beal AC, Chou SC, Palmer RH, Testa MA, Newman C, Ezhuthachan S. Related Articles,
The changing face of race: risk factors for neonatal hyperbilirubinemia. Pediatrics. 2006
May;117(5):1618-25. (PMID: 16651315)
87. Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RT, Riggs SA.
Treatment of Mild Anemia: a Randomized Trial of Epoetin Alfa in Patients Receiving
Chemotherapy for Hematologic Malignancies, Cancer, 2006;107:1909-1917.
(PMID:16977654)
88. Meaney PA, Nadkarni VM, Cook EF, Testa M, Helfaer M, Kaye W, Larkin GL, Berg RA;
American Heart Association National Registry of Cardiopulmonary Resuscitation
Investigators. Higher survival rates among younger patients after pediatric intensive care
unit cardiac arrests. Pediatrics. 2006;118:2424-33. (PMID: 17142528)
89. Dorn BC, Savoia E, Testa MA, Stoto MA, Marcus LJ. Development of a survey instrument
to measure connectivity to evaluate national public health preparedness and response
performance. Public Health Rep. 2007 May-Jun;122(3):329-38. (PMID: 17518304 PMCID:
PMC1847495)
90. Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled versus
injected insulin in adolescents and adults with type 1 diabetes. Diabetes Care. 2007;
30:1399-1405. (PMID: 17337493)
91. Marc LG, Testa MA, Walker AM, Robbins GK, Shafer RW, Anderson NB, Berkman LF;
ACTG Data Analysis Concept Sheet Study Team. Educational attainment and response to
15
HAART during initial therapy for HIV-1 infection. J Psychosom Res. 2007 Aug;63(2):20716. PMID: 17662759
92. Smitten AL, Choi HK Hochberg MC, Suissa A, Simon TA, Testa MA, Chan KA. The risk
of herpes zoster in patients with rheumatoid arthritis in the United States and the United
Kingdom. Arthritis Rheum. 2007 Dec 15;57(8):1431-8. (PMID: 18050184)
93. Reynolds NR, Testa MA, Su M, Chesney MA, Neidig JL, Frank I, Smith S, Ickovics J,
Robbins GK; for the AIDS Clinical Trials Group 731 and 384 Teams. Telephone support to
improve antiretroviral medication adherence: A multisite, randomized controlled trial. J
Acquir Immune Defic Syndr. 2008 Jan 1;47(1):62-8.( PMID: 17891043)
94. Smitten AL, Choi HK Hochberg MC, Suissa A, Simon TA, Testa MA, Chan KA. The risk
of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008
Mar;35(3):387-93 (PMID: 18260176)
95. Savoia E, Testa MA, Biddinger PD, Cadigan RO, Koh H, Campbell P, Stoto MA.
Assessing public health capabilities during emergency preparedness tabletop exercises:
reliability and validity of a measurement tool. Public Health Rep. 2009 JanFeb;124(1):138-48. (PMID:19413036 PMCID: PMC2602939)
96. Bode B, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A. Patientreported outcomes following treatment with the human GLP-1 analogue liraglutide or
glimepiride in monotherapy: results from a randomized controlled trial in patients with type
2 diabetes. Diabetes Obes Metab. 2010; 12:604-12. (PMID: 20590735 PMCID:
PMC2901519100)
97. Henderson E, Testa MA, Hartnick C. Prevalence of noise-induced hearing-threshold
shifts and hearing loss among US youths. Pediatrics 2011 127(1):e39-46.
(PMID:21187306)
98. Marc LG, Zerden M, Ferrando S, Testa MA. HIV+ caregivers and HIV+ non-caregivers:
differences in sociodemographics, immune functioning and quality-of-life. AIDS Care.
2011; 23:880-91. (PMID: 21400310 PMCID: PMC3125425102).
99. Bailey EE, Marghoob AA, Orengo IF, Testa MA, White VR, Geller AC. Skin cancer
knowledge, attitudes, and behaviors in the salon: a survey of working hair professionals in
Houston, Texas. Arch Dermatol. 2011 Oct;147(10):1159-65. (PMID: 22006132).
100. Savoia E, Testa MA, Viswanath V. Predictors of knowledge of H1N1 infection and
transmission in the U.S. population. BMC Public Health 2012,12:328 doi:101.1186/14712458-12-328. (PMID: 22554124)
101. Testa MA, Gill J, Su M, Turner RR, Blonde L and Simonson DC. Comparative
effectiveness of basal-bolus versus premix analogue insulin on glycemic variability and
patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: A
randomized, controlled, cross-over trial. J Clin Endocrinol Metab. 2012; 97:3504-14.
(PMID: 22851487)
102. Nanda A, Khan IS, Goldman R, Testa M. Sports-related concussions and the Louisiana
Youth Concussion Act. J La State Med Soc. 2012 Sep-Oct;164(5):246-50. (PMID:
23362587)
103. Marc LG, Wang, MM, Testa MA. Psychometric evaluation of the HIV symptom distress
scale. AIDS Care. 2012 AIDS Care, 2012; 24:1432-41 (PMID: 22409246 PMCID:
PMC3436989)
16
Book Chapters
1. Testa MA and Spencer RP. Monitoring of kinetic in vivo radiopharmaceutical data:
Linear models analysis of Michaelis-Menten parameters. In Interventional Nuclear
Medicine (RP Spencer, Ed.), Grune and Stratton, pp. 609-610, 1984.
2. Williams GH and Testa MA. Quality of life: An important consideration in
antihypertensive therapy. In Management of Hypertension: A Multifactorial
Approach (NK Hollenberg, Ed.), Scientific Therapeutics Information, Butterworth
Publishers, Stoneham, MA, 1987, pp. 79-100.
3. Max S and Testa MA. A Latent Variable Growth Model Approach to Analyzing
Multiple Health Outcomes from Clinical Trials pages 113 – 138 Book Chapter 6 in
Advancing Health Outcomes Research Methods and Clinical Applications (Eds)
William R. Lenderking & Dennis A. Revicki, 386 pages; ISBN 0-9656837-4-5,
386pp.
4. Testa M and Simonson D. The Use of Questionnaires and Surveys. In: Robertson D
and Williams G Clinical and Translational Sciences. London: Elsevier. 2009 Chapter
9, pp 137-153.
5. Cook EA and Testa MA. Quality of Health Care. In The Diabetic Foot: Medical and
Surgical Management. Part IV Organization and Preventive Care. Chapter 24. Veves
A, Giurini JM and LoGerfo FW (Eds). Springer, New York, 2012 pp. 481 – 502.
Selected Published Abstracts – Major Scientific Meetings – past 15 years
1. Testa MA, Gill J, Su M, Turner RR, Traylor and Simonson DC. Improved glycemic control
and variability during insulin intensification improve patient-centered outcomes in type 1
diabetes. Diabetes 2012; 61 Supplement 1, 805-P A204.
2. Simonson DC, Gill J, Su M, Turner RR, Traylor and Testa MA. Assessing the Comparative
Effectiveness (CE) of Basal-Bolus vs.Premix Insulin Using Continuous Glucose Monitoring
(CGM) Summary Measures. Diabetes 2012; 61 Supplement 1, 850-P A216.
3. Testa MA and Simonson DC. Physician and Patient Usability of A Web-Based MobileHealth Diabetes Management System. Diabetes. 60 Supplement 1, 907-P A247, 2011.
4. Testa MA, Blonde L, Gill J, Turner RR, Simonson DC. Decreased Glycemic Variability
during Insulin Therapy Improves Patient Centered Outcomes in Type 1 and 2 Diabetes, Late
Breaking Abstract, 70th Scientific Session, American Diabetes Association, June 25 - 29,
2010; Orlando, Florida.
5. Testa MA, Blonde L, Gill J, Turner RR, Simonson DC. Patient-centered outcomes and
glycaemic variability in type 1 and type 2 diabetes: a cross-over trial of insulin glargine +
glulisine vs premix analogue insulin. 46th EASD Annual Meeting, Stockholm, Sweden,
September 2010, Diabetologia, 2010.
6. Simonson DC, Testa MA ,Gill J, Turner RR, Blonde L. 1056 - Predictors of continuous
17
glucose monitoring (CGM) variability and associations with patient satisfaction and health
perceptions in insulin-treated diabetes. 46th EASD Annual Meeting, Stockholm, September
2010, Diabetologies, 2010.
7. Simonson DC, Testa MA ,Turner RR. Electronic Diary and Internet-based Clinical
Monitoring of Hypoglycemia during Intensive Insulin Titration in Type 1 and Type 2
Diabetes. Diabetes. 58 Supplement 1, 269-OR, 2009.
8. Testa MA, Turner RR Simonson DC. Patient Adherence and Accuracy using Electronic
Diaries during Remote Patient Monitoring in Type 1 and Type 2 Diabetes, Diabetes. 58
Supplement 1, 1211-P, 2009.
9. Testa MA, Turner RR, Hayes JF, Simonson DC. Patient-Reported Quality of Life and
Satisfaction Outcomes in Type 2 Diabetes: A Randomized Trial of Combination Therapies,
Diabetes. 58 Supplement 1, 1882-P, 2009.
10. Bode B, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A. Patientreported outcomes following treatment with the human GLP-1 analog liraglutide in
monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Diabetologia, 2008.
11. Testa MA, Turner RR, Simonson DC. Feasibility and Validation of an Electronic Patient
Diary and Internet-Based Clinical Management System in Insulin-Treated Type 1 and 2
Diabetes Patients. 1168-P. Diabetes. 55 Supplement 1:A275, June 2006.
12. Testa MA, Turner RR, Simonson DC.Reducing Barriers to Insulin Use in Persons Aged 65
Years and Older: A Comparison of Inhaled and Injectable Insulin, 429-P. Diabetes. 55
Supplement 1:A102, June 2006.
13. Simonson DC, Turner RR, Testa, MA. Simonson DC Validity of Glycemic Variability and
Control Assessed by 4-Point Profiles vs Continuous Glucose Monitoring, 1952-PO. Diabetes.
55 Supplement 1:A451, June 2006.
14. Testa MA, Hayes JF, Turner RR, Simonson DC. Quality of Life Improvements in Type 2
Diabetes when Exubera is Added after Failure on Metformin Monotherapy: An International
Randomized Phase 3 Trial. Diabetes. 53 Supplement 2:A437, June 2004.
15. Scranton RE, Su M, Turner RR, Testa MA. Quality-of-Life Considerations for Insulin versus
Oral Agent Therapy in Persons Presenting with Characteristics of Latent Autoimmune
Diabetes in Adults (LADA). Diabetes. 53 Supplement 2:A438, June 2004.
16. Testa MA, Turner RR, Hayes JF, Scranton RE, Simonson DC. Satisfaction and Quality of
Life with Sulfonylurea Plus Either Metformin or Exubera: An International Randomized
Phase 3 Trial. Diabetes. 53 Supplement 2:A115, June 2004.
17. Reynolds NR, Testa MA, Su, M, Chesney MA, Robbins GG for the Protocol Teams of
ACTG 384 Baseline predictors of adherence to antiretrovirals in treatment naive HIV+
subjects (ACTG 384) and subsequent regimen failure. 2nd IAS Conference on HIV
Pathogenesis and Treatment, Paris, July 13 – 16, 2003.
18. Thompson M, Turner R, Su M, Testa MA, Kotler D, Gertner J, , Muurahainen N.
Recombinant human growth hormone (rhgh) enhances patient-reported body image and
improves quality of life in HARS (HIV-associated adipose redistribution syndrome). 2nd IAS
Conference on HIV Pathogenesis and Treatment, Paris, July 13 – 16, 2003.
19. Testa MA, Hayes JF, Turner RR, Simonson DC. Obesity in Type 2 diabetes is associated
with reduced quality of life. Diabetes 2003; 52 (Suppl 1): A39.
20. Testa MA, Turner RR, Simonson DC. Effects of lower blood glucose and reduced inter-day
18
glucose variability on quality of life in type 2 diabetes. Diabetes 2003; 52 (Suppl 1): A420.
21. Fletcher CV, Testa MA, Haubrich R, Brundage R, Jiang H, Ickovics J, Martinez A,
Snyder S, Gulick R.Relationships among Four Measures of Medication Adherence and
Virologic Response in ACTG 359, 10th Conference on Retrovirus and Opportunistic
Infections, Boston, February 10 – 14, 2003.
22. Straus DJ, Turner RR, Testa MA, Hayes JF, Sarokhan BJ and the Procrit Hematologic
Malignancies Study Group. Epoetin Alfa Treatment Improves Quality of Life and Increases
Hemoglobin Levels during Chemotherapy for Lymphoma, Chronic Lymphocytic Leukemia
(CLL), and Multiple Myeloma (MM) Patients with Mild-to-Moderate Anemia. 44th Annual
American Society of Hematology Meeting and Exposition, Philadelphia, December 6-10,
2002
23. Testa MA, Thompson M, Turner RR , Muurahainen N , Gertner JM. The impact of HIVassociated adipose redistribution syndrome on psychological well-being and quality of life: A
cross-sectional survey. XIV International AIDS Conference, Barcelona, July 7 – 12, 2002.
24. Kotler DP, Thompson M, Grunfeld C, Testa MA, Turner R, Joseph Gertner J, Muurahainen
N. Growth Hormone (Serostimreg;) effectively reduces viceral adipose tissue (VAT)
accumulation and non-HDL cholesterol. XIV International AIDS Conference, Barcelona, July
7 – 12, 2002.
25. Reynolds NR, Testa MA, Marc LG, Chesney MA, J L Neidig JL, Smith SR, Vella S,
Robbins GG. Psychosocial influences of attitudes and beliefs toward medication adherence in
HIV+ persons naive to antiretroviral therapy: A cross-sectional survey. XIV International
AIDS Conference, Barcelona, July 7 – 12, 2002.
26. Testa MA, Turner RR, Hayes JF, Simonson DC. Patient satisfaction with insulin therapy in
type 2 diabetes: A randomized trial of injectable vs. inhaled insulin. Diabetes 2002; 51
(Suppl 2): A135.
27. Su M, Testa MA, Turner RR and Simonson, DC. The relationship between regimen burden
and psychological well being in persons with type 2 diabetes: Inhaled vs. injectable insulin.
Diabetes 2002; 51 (Suppl 2): A448-449.
28. Testa MA, Hayes JF, Turner RR, Simonson DC. Differential effects of reducing fasting vs
post-prandial glucose on symptoms of hyperglycemia and hypoglycemia in type 2 diabetes.
Diabetes 2002; 51 (Suppl 2): A478.
29. Testa MA, Turner RR, Hayes JF, Simonson DC. Intensive therapy and patient satisfaction in
type 1 diabetes: A randomized trial of injected vs. inhaled insulin. Diabetologia 2001;
44(suppl1); A4.
30. Turner RR, Testa MA, Hayes JF, Simonson DC. Patient satisfaction with intensive insulin
therapy in type 2 diabetes: A randomized trial of insulin pen vs. pump. Diabetologia 2001;
44(Suppl1): A26.
31. Testa MA, Turner RR, Hayes JF, Simonson DC. Patient acceptance and satisfaction with
intensive insulin therapy in type 2 diabetes: A randomized trial of the insulin pen vs. pump.
Diabetes 2001; 50 (Suppl 2): A428.
32. Simonson DC , Hayes JF, Turner RR Testa MA,. Treatment satisfaction and preferences in
type 2 diabetes: A randomized trial of oral agents vs. inhaled insulin.. Diabetes 2001; 50
(Suppl 2): A131.
33. Testa MA, Turner RR, Hayes JF, Simonson DC. Patient satisfaction and quality of life in
type 1 diabetes: A randomized trial of injectable vs. inhaled insulin. Diabetes 2001; 50
19
(Suppl 2): A45.
34. Testa MA, Hayes JF, Turner RR, Simonson DC. Improved quality of life is associated with
improved glycemic control in type 2 diabetes: An international, multi-cultural, multi-center,
placebo-control clinical trial. Diabetes 2000 49(Suppl 1): A73.
35. Simonson DC and Testa MA. Estimating rates of myocardial infarction in patients with type
2 diabetes on oral antidiabetic medications using an insurance claims database. Diabetes
1999, 48 (Suppl 1): A398.
36. Blonde L, Guthrie RD, Testa MA, O’Brien TW, Zimmerman RS, Sandberg MI, Theodoras
SH, Parkes JL, Ginsberg BH. Diabetes Management by a team of diabetes nurse educators,
endocrinologists and primary care physicians in a managed care environment. Diabetes
1999, 48 (Suppl 1): A198.
37. Testa MA, Hayes JF, Turner RR, Simonson DC. Tolerance of Glipizide GITS (GITS) vs.
Metformin (MET) and the impact on health care utilization as measured by patient SelfReports. Diabetes 1999, 48 (Suppl 1):A116.
38. Testa MA, Blonde l, Hayes JF, Simonson DC. Symptom and psychological mediators of
improved quality of life (QOL) during stages diabetes management (SDM) versus Usual Care
(UC) in type 2 diabetes. Diabetes 1999 (Suppl 1), 48:A9.
39. Simonson DC and Testa MA. Health care expenditures during progression from oral agent
to insulin therapy in type 2 diabetes. Diabetes 1998 (Suppl 1), 47:A59.
40. Simonson DC and Testa MA. Cost of oral antidiabetic therapy in patients with type 2
diabetes. Diabetes 1998 (Suppl 1), 47:A60.
41. Testa MA, Turner RA, Simonson DC. Evaluating patient preferences for states of health
and quality of life in persons with Type 2 diabetes. Diabetes 1998 (Suppl 1), 47:A324.
42. Turner R, Testa M, Krafcik MB, Simonson D, Esteban E, Manero M, Luque M. Differential
effect of calcium channel blockade on patient quality of life: Nifedipine GITS vs. Amlodipine
in mild to moderate hypertension. Drug Information Journal 1998: 4;1434-1435
43. Testa M and Simonson D. Health economic benefits of improved glycemic control. Diabetes
1997 (S1), 47:36A
44. Testa M and Simonson D. Beneficial effects of improved glycemic control with glipizide
GITS on quality of life and symptoms in NIDDM. Diabetologia 1996: 39 (Suppl 1); A231
45. Testa MA, Simonson DC. Beneficial effects of improved glycemic control with glipizide
GITS on quality of life and symptom distress in NIDDM. Diabetes. May 1996;45(Suppl 2):
123A Abstract 450.
46. Turner RR and Testa MA. Increasing utility weight sensitivity to change: the functional
range. Journal D'Economic Medicale, 1996.
20

Marcia A. Testa, M.P.H., M.Phil., Ph.D. 23 Woodcliff Road Department of Biostatistics

Transcription

Similar documents